208 results about "Galactosidases" patented technology

The invention provides application of scEMC10 in treatment and diagnosis of cerebral vascular endothelial cell senescence, and relates to the technical field of biomedicine. The research of the inventor finds that brain microvascular endothelial cell senescence is caused by the lack of scEMC10; after the brain microvascular endothelial cells are treated by scEMC10, beta-galactosidase, SASP and classic senescence markers related to senescence can be down-regulated; after scEmc10 is supplemented to old mice and Alzheimer's disease 5XFAD model mice, the motion coordination ability and the spatial cognitive ability of the mice can be obviously improved, the relative content of a marker phosphorylated alpha-synuclein of the Parkinson's disease of the old mice can be obviously reduced, and the content of tyrosine hydroxylase phosphorylated active forms can be increased. Therefore, the scEMC10 can be used for treating brain microvascular endothelial cell senescence, improving Alzheimer's disease and Parkinson's disease and detecting brain microvascular endothelial cell senescence as a marker.

The invention provides an anti-aging composition and application thereof, the composition at least contains pyrroloquinoline quinone disodium salt, ergothioneine and 5-aminolevulinic acid or salt thereof in physiologically acceptable media, the composition contains PQQ, ergothioneine and 5-aminolevulinic acid (5-ALA) or salt thereof, the three components are compounded to achieve a synergistic effect, and the anti-aging effect is achieved. The dyeing intensity of beta-galactosidase is reduced, and the anti-aging effect is achieved.

The invention belongs to the technical field of analysis and detection, and particularly relates to a beta-galactosidase response type hemicyanine near-infrared fluorescent probe, a preparation method thereof and application of the beta-galactosidase response type hemicyanine near-infrared fluorescent probe as a tumor organ imaging probe. The near-infrared fluorescent probe provided by the invention takes a water-soluble hemicyanine skeleton as a fluorophore, so that the biocompatibility of the near-infrared fluorescent probe is improved; based on the principle that beta-galactose can be selectively cut by beta-galactosidase, a galactose structure with a self-leaving group is used as a response group, selective quick response to the beta-galactosidase is achieved, and high sensitivity to the beta-galactosidase is shown. The near-infrared fluorescent probe provided by the invention can emit near-infrared fluorescence with long wavelength, has lower background fluorescence and good penetration depth, and can be directly used for detecting organoids containing the matrigel without eliminating the matrigel, so that the organoids are prevented from being damaged or additional experimental variables are prevented from being introduced in the process of eliminating the matrigel.

The invention relates to the technical field of prebiotics preparation, and discloses a preparation method of prebiotics applied to reproduced areca catechu, and the preparation method comprises the following steps: carrying out enzyme catalysis reaction on sucrose by adopting fructosyl transferase to prepare fructo-oligosaccharide; according to the method, beta-galactosidase is adopted to carry out enzyme catalysis reaction on lactose, so that galactooligosaccharide is prepared; respectively carrying out decoloration, ion exchange, nanofiltration concentration and spray drying on the candy oligosaccharide and the galactooligosaccharide to obtain powder; the method comprises the following steps: mixing fructo-oligosaccharide powder and galactooligosaccharide powder according to a ratio, and uniformly distributing the mixture in a reproduced areca-nut matrix by adopting a spray-drying blending or low-temperature vacuum mixing mode to form a functional reproduced areca-nut product; according to the invention, low-temperature drying is carried out on the product after blending or vacuum mixing, so that the prebiotic areca nuts are released along with saliva in the chewing process, and are selectively utilized by bifidobacteria and lactic acid bacteria after entering the stomach and intestine, thereby achieving the purposes of regulating intestinal flora and improving the health-care function.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The invention discloses a pharmaceutical composition for delaying oocyte senescence and application thereof, and relates to the technical field of biological medicine, and the pharmaceutical composition comprises alpha-ketoglutaric acid, a bicarbonate buffer solution, an energy metabolism substrate, polyvinyl alcohol, hormone, a growth factor and insulin-transferrin-selenium. The pharmaceutical composition for delaying oocyte aging disclosed by the invention is beneficial to improving the maturation rate of oocytes, reducing the cytoplasm fragmentation rate and the cleavage fragmentation rate, and improving the cleavage rate and the blastocyst rate; according to the invention, the content of beta-galactosidase is reduced, the function of mitochondria in the aging process after ovulation of the mature oocyte is improved, the membrane potential of the mitochondria in the aging process after ovulation of the mature oocyte is stabilized, the activity of the mitochondria is improved, and the normalization of RNA methylation modification in the aging process after ovulation of the mature oocyte is promoted.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The application discloses efficient expression of Aspergillus oryzae beta-galactoside enzyme mutant and application thereof in dairy products, and belongs to the technical fields of enzyme engineering and dairy product processing, and particularly relates to efficient expression of Aspergillus oryzae beta-galactoside enzyme mutant and application thereof in dairy products.The mutant protein can be as follows: A1) a protein with an amino acid sequence of SEQ ID No.2; A2) a fusion protein with the same function obtained by connecting a label to the N terminal and / or C terminal of A1).The mutant protein is subjected to high-density fermentation in a 5L fermentation tank, and the enzyme activity of the fermentation liquor can reach 4628U / mL, and the recovery rate of the mutant enzyme is increased by 1.7 times.Compared with the wild type, the optimal pH of the mutant is increased from 4.5 to 5.5, the optimal temperature is decreased from 60 DEG C to 50 DEG C, the lactose hydrolysis efficiency is increased by 11%, and the mutant is more suitable for the production process of low / zero lactose dairy products.

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

The invention relates to a beta-galactosidase mutant with improved thermal stability and pH stability, and belongs to the technical field of enzyme engineering. The beta-galactosidase derived from Kluyveromyces lactis is subjected to molecular modification, a potential mutation site is determined by using an alanine scanning strategy, beta-galactosidase mutants Pro433Ala and Asp441Ala of which the thermal stability and the pH stability are simultaneously improved are obtained through site-directed mutagenesis screening, the catalytic efficiency of the mutants is improved to 1.03-1.18 times compared with that of the mutants before optimization, and the beta-galactosidase mutant can be used for preparing beta-galactosidase. Wherein the maximum half-life period of the mutant Asp441Ala under the condition of 50 DEG C reaches 91.5 minutes and is increased by 213.4% compared with that of a wild type, the problems of poor catalytic thermal stability and poor pH stability of beta-galactosidase in the prior art are solved, and a brand-new tool is provided for obtaining galactooligosaccharide by using beta-galactosidase to hydrolyze lactose.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

Described herein are novel engineered peptides, viral vectors, and pharmaceutical compositions thereof, and uses of the same for increasing α-GAL A expression and for the treatment of conditions associated with α-GAL A deficiency, such as Fabry disease.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta-galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta-hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).

A composition including a gene therapy delivery system and an alpha-galactosidase (GLA) polynucleotide encoding a GLA polypeptide, wherein the GLA polypeptide has at least 95% sequence identity to one of SEQ ID NOS. 1-40, 44-45, 51-52, 57, 61-173 or 212. Also provided are compositions, formulations, fusion proteins, and methods for the treatment of Fabry disease.

The present invention discloses a photosensitizer prodrug compound (structural formula (I)) that selectively clears senescent cells and is specifically activated by the aging-associated β-galactosidase, as well as its preparation method and application. Upon activation by β-galactosidase, the compound rapidly releases its active molecule, anchoring it to proteins with nucleophilic groups. This allows for precise detection and covalent anchoring of senescent cells, thereby achieving selective clearance of senescent cells, reversing senescence-related markers and gene expression, and ameliorating aging-related decline in bodily functions. #imgabs0#

The invention relates to the technical field of daily cosmetics, in particular to a peony extract with scalp anti-aging and anti-hair-loss functions and application. The peony extract disclosed by the invention is a peony flower extract, the mass fraction of peony flower peptide in the peony flower extract is greater than or equal to 10%, and the peony extract disclosed by the invention is found to have the effects of improving the activity of superoxide dismutase (SOD) on human hair papilla cells for the first time; the positive cell rate of beta-galactosidase (SA-beta-Gal) of human hair papilla cells is inhibited, and the functions of senescent cells are reduced; meanwhile, the functions of promoting hair follicles to express growth factors and promoting hair growth are achieved. The method can be applied to preparation of scalp care products, and the anti-aging or anti-hair-loss function of scalp is achieved.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The invention provides a near-infrared beta-galactosidase fluorescent probe as well as preparation and application thereof, and relates to the technical field of fluorescent probes, according to the near-infrared beta-galactosidase fluorescent probe, when beta-galactosidase exists, a D-galactosyl group can be split, meanwhile, self-elimination of p-hydroxybenzyl is removed, a fluorescent signal unit is released, and the beta-galactosidase can be detected by the near-infrared beta-galactosidase fluorescent probe. The fluorescence signal is obviously enhanced. Excitation and emission spectra of the near-infrared beta-galactosidase fluorescent probe are both in a near-infrared region, the fluorescence intensity at 760 nm is rapidly increased, the fluorescence intensity rapidly reaches a stable state after 30 min, and compared with a visible light probe, the near-infrared beta-galactosidase fluorescent probe has deeper tissue penetrating capacity, background interference can be effectively avoided, and the resolution ratio is improved; the compound can be applied to beta-galactosidase detection imaging and preparation of beta-galactosidase detection imaging reagents, especially breast cancer detection reagents.

The application discloses a high-temperature-resistant alkaline alpha-galactosidase mutant and a preparation method thereof. The mutant is obtained by performing site-directed mutation on alpha-galactosidase derived from Anoxybacillus vitaminiphilus, and at least one amino acid in three positions of 444th, 457th and 509th in the amino acid sequence shown in SEQ ID No. 1 is replaced. The asparagine Asn in the 444th position is mutated into phenylalanine Phe, the aspartic acid Asp in the 457th position is mutated into methionine Met, and the arginine Arg in the 509th position is mutated into tryptophan Trp. The alpha-galactosidase mutant has good thermal stability and alkali stability by performing site-directed mutation on alpha-galactosidase derived from Anoxybacillus vitaminiphilus (Anoxybacillus vitaminiphilus WMF1).

Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

The application belongs to the technical field of microorganisms, and particularly relates to a Bifidobacterium breve RRJK1316 capable of promoting digestion and application thereof. Bifidobacterium breve The Bifidobacterium breve is named as Bifidobacterium breve (RRJK1316), is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No. 64764. The strain has strong acid and bile salt resistance, can effectively resist the influence of gastric juice, and can maintain high activity after passing through the digestive tract. The strain has strong digestion promotion function, and the digestion promotion function is better than that of domperidone 75.0 mu g / mL when the concentration of live bacteria is 6.00*10 8 CFU / mL. Meanwhile, the strain has the function of relieving lactose intolerance, and the beta-galactoside enzyme activity reaches 0.793 U / mL.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a fluorescent probe as well as a preparation method and application thereof. The SA-beta-gal fluorescent probe prepared by the invention is novel in structure, high in sensitivity, high in response speed and excellent in pH stability, and can be used for detecting the activity of beta-galactosidase in cells, tissues and living bodies in real time; the obtained fluorescent probe compound is used for evaluating the feasibility of the curative effect of the anti-aging drug, the drug screening process can be completed by a single person within several days, and the period and cost of an existing anti-aging drug screening method at present are greatly shortened; in addition, according to the preparation method of the SA-beta-gal fluorescent probe, raw materials are easy to obtain, reaction conditions are controllable, synthesis is simple, and the SA-beta-gal fluorescent probe has a wide application prospect.

The invention discloses a method for preparing galacto-oligosaccharides, comprising the following steps: S1, using a lactose solution as a raw material, loading a barrier layer with beta-galactosidase immobilized by calcium pectin gel-chitosan, wherein the calcium pectin gel-chitosan as a carrier is composed as follows: chitosan is assembled on the surface of calcium pectin gel particles by electrostatic adsorption, and the beta-galactosidase is cross-linked to the chitosan; S2, circulating, wherein the lactose solution flows through the surface of the calcium pectin gel-chitosan and contacts with the beta-galactosidase for reaction; S3, pumping out the reaction solution, separating the galacto-oligosaccharides using a continuous simulated moving bed technology, and recovering the separated lactose to continue the reaction; the invention uses the calcium pectin gel particles as the core, gathers chitosan on the surface of the gel particles, further adsorbs and cross-links the beta-galactosidase, and cooperates with the liquid circulation during the reaction process to effectively improve the conversion rate of the galacto-oligosaccharides.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

The invention belongs to the technical field of natural pigments, and particularly relates to a method for improving the performance of blueberry anthocyanin by using tamarind polysaccharide. According to the method for improving the performance of the blueberry anthocyanin by utilizing the tamarind polysaccharide, after a tamarind polysaccharide solution and a blueberry anthocyanin solution are prepared, the tamarind polysaccharide which is not subjected to enzymolysis or the tamarind polysaccharide which is subjected to enzyme treatment such as beta-galactosidase and the like is added into the blueberry anthocyanin solution for mixing; a blueberry anthocyanin stable solution is obtained; blueberry anthocyanin and tamarind polysaccharide in the blueberry anthocyanin stabilizing solution are compounded through non-covalent bonds such as hydrogen bonds, so that the stability of the blueberry anthocyanin in light, heat and digestive systems is improved, the oxidation resistance is enhanced, and the color is improved; therefore, the technical problem that the performance of the blueberry anthocyanin is easily reduced at present is solved.

Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

The invention relates to a polynucleotide comprising a lacZ gene (lacZFS) encoding a β-galactosidase characterized by a particular profile with respect to its lactose hydrolysis efficiency. The invention also relates to a strain of Streptococcus thermophilus comprising a lacZFS allele and a bacterial composition thereof, and its use for obtaining fermented milk that does not undergo subsequent acidification.

To provide methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone.SOLUTION: The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.SELECTED DRAWING: None

The invention relates to the technical field of traditional Chinese medicine compositions, and provides a traditional Chinese medicine composition for removing acnes, which is prepared from the following components in parts by weight: 1-2 parts of honeysuckle stem extract, 0.3-0.8 part of fructus forsythiae extract, 2-4 parts of radix scutellariae extract, 0.5-3.5 parts of cortex magnoliae officinalis extract and 1-5 parts of astragalus complanatus extract. The preparation method of the fructus forsythiae extract comprises the following steps: crushing fructus forsythiae, performing steam explosion treatment to obtain pretreated fructus forsythiae, adding water, adding biological compound enzyme, performing enzymolysis, filtering and performing enzyme deactivation to obtain filtrate; enabling the filtrate to pass through macroporous resin, washing with water, carrying out first elution to obtain a solution I, and carrying out second elution to obtain a solution II; performing post-treatment on the solution I to obtain forsythiaside; performing post-treatment on the solution II to obtain forsythin; the biological compound enzyme comprises alpha-galactosidase, lipase and xylanase. Through the technical scheme, the problem of low extraction rate of forsythin and forsythiaside in fructus forsythiae in the prior art is solved.